维普中文期刊产品整合服务
59篇 您的检索式:作者名="COUDERT B"
    题名 作者 年代 出处 被引量
1Use of-FDG PET to predict response to neoadjuvant trastuzumab and docetaxel in patients with HER2-positive breast cancer, and addi- tion of bevacizumab to neoadjuvant trastuzumab and doeetaxel in -FDG PET-predicted non-responders ( AVATAX- HER) : an open-label, randomised phase 2 trial显示文摘Coudert B Pierga JY Mouret-Reynier MA 2014Lancet On- col2014,15,13:1
2Novel tubulin-tar- geting agents: anticancer activity and pharmacologic profile of epothilones and related analogues 显示文摘FUMOLEAU P COUDERT B ISAMBERT N 2007Ann Oncol2007,18,:1
3Novel tubulin-targeting agents:anticancer activity and pharmacologic profile of epothilones and related analogues显示文摘Fumoleau P Coudert B Isambert N 2007Ann Oncol2007,18,5:1
4Targeting ErbB receptors in breast cancer 显示文摘FUMOLEAU P CAMPONE M COUDERT B 2007Bull Cancer2007,94,7:1
5Phase II study of XR 5000 (DACA), an inhibitor of topoisomerase I and II ,administered as a 120-h infusion in patients with non-small cell lung cancer显示文摘Dittrieh C Coudert B Paz-Ares L 2003Eur J Cancer2003,39,3:1
6It's time for chronotherapy!显示文摘Coudert B Focan C Donato di Paola E 0,,4:1
7Pathological complete re- sponse and survival according to the level of HER-2 amplification after trastuzumab-based neoadjuvant therapy for breast caucer显示文摘Guiu S Gauthier M Coudert B 2010BrJ Cancer2010,103,9:1
8Novel tubu- lin targeting agents: anticancer activity and pharmacologic profile of epothilones and related analogues 显示文摘Fumoleau P Coudert B Isambert N 2007Ann Oneol2007,18,5:1
9Diagnostic and predictive value of skin testing in platinum salt hyper- sensitivity 显示文摘Leguy-Seguin V Jolimoy G Coudert B 2007J Allergy Clin Immunol2007,119,3:1
10How different steel grades react to a salt bath nitroearburizing and post-oxida- tion process: influence of alloying elements 显示文摘Jacquet P Coudert J B Lourdin P 2011Surface & Coatings Technology2011,205,16:1
11Knowledge formaliza- tion in experience feed back processes:An ontology based approach 显示文摘Kamsu F B Coudert T Beler C 2008Computers in Industry2008,,59:1
12Pathological complete re- sponse and survival according to the level of HER 2 amplification after trastuzumab-based neoadjuvant therapy for breast cancer 显示文摘Guiu S Gauthier M Coudert B 2010BrJ Caneer2010,103,9:1
13Management of metastatic HER2-positive breast cancer: present and future 显示文摘GUIU S COUDERT B FAVIER L 2010Bull Cancer2010,97,3:1
14Diagnostic and predictive value of skin testing in platinum salt hypersensitivity显示文摘Leguy-Seguin V Jolimoy G Coudert B 2007Journal of Allergy and Clinical Immunology2007,119,3:1
15Randomized multicenter phase Ⅱ study comparing a combination,of fluorouracil and folinic acid and alternating irinotecan and oxaliplatin with oxaliplatin and irinotecan in fluorouracil-pretreated metastatic colorectal cancer patients显示文摘BECOUARN Y GAMELIN E COUDERT B 2001J Clin Oncol2001,19,22:1
16Rabbit model of induced Pneumocystis carinii development followed by reinfection 显示文摘Cere N Polack B Coudert P 1997J Eukaryot Microbiol1997,44,6:1
17Glutathione S-transferase M1 null genotype: lack of association with tumour characteristics and survival in advanced breast cancer显示文摘Lizard-Nacol S Coudert B Colosetti P 1999Breast Cancer Research1999,1,1:1
18Survival benefit with erlotinib maintenance therapy in patients with advanced non-small-cell lung cancer (NSCLC) according to response to first-line chemotherapy显示文摘Coudert B Ciuleanu T Park K 2012Annals of Oncology2012,23,2:1
19Randomized multicenter phase Ⅱ study comparing a combination of fluorouracil and folinic acid and altemating irinotecan and oxaliplatin with oxaliplatin and irinotecan in fluorouracil-pretreated metastatic colorectal cancer patients显示文摘Becouarm Y Gamelin E Coudert B 2001J Clin Oncol2001,19,22:1
20High purity microfluidic sorting and analysis of circulating tumor cells:towards routine mutation detection显示文摘Autebert J Coudert B Champ J 2015Lab Chip2015,15,9:1
返回顶部 每页显示:
共3页 首页 上一页 第1页 下一页 末页 /3 跳转

网站首页 | 关于我们 | 联系我们 | 产品服务 | 客服中心 | 广告服务 | 版权声明 | 网站联盟 | 友情链接 | 售卡网点

版权所有© 渝B2-20050021-1 渝公网安备 50019002500403号 违法和不良信息举报中心

互联网出版许可证 新出网证(渝)字10号 全国400电话 - 免长途话费